Data by Company within Medical Laboratories Industry
|
| |
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
| Company |
(Millions) |
(Millions) |
(Millions) |
Number |
| Iqvia Holdings Inc |
$ 37,948 |
$ 14,681 |
$ 1,096 |
79,000 |
| Ge Healthcare Technologies Inc |
$ 30,448 |
- |
$ 0 |
- |
| Icon Plc |
$ 20,651 |
$ 7,741 |
$ 505 |
15,950 |
| Koninklijke Philips Nv |
$ 18,094 |
$ 19,966 |
$ -1,798 |
82,000 |
| Hologic Inc |
$ 17,316 |
$ 4,038 |
$ 1,667 |
6,944 |
| Ppd Inc |
$ 16,999 |
- |
$ 0 |
- |
| Quest Diagnostics Inc |
$ 14,215 |
$ 9,488 |
$ 858 |
49,000 |
| Incyte Corporation |
$ 13,257 |
$ 3,513 |
$ 366 |
2,094 |
| Exact Sciences Corporation |
$ 11,883 |
$ 2,292 |
$ -432 |
5,361 |
| Pra Health Sciences Inc |
$ 10,932 |
$ 3,333 |
$ 213 |
35,000 |
| Charles River Laboratories International inc |
$ 10,053 |
$ 4,178 |
$ 490 |
20,000 |
| Medpace Holdings Inc |
$ 7,726 |
$ 1,673 |
$ 269 |
3,900 |
| Natera Inc |
$ 5,139 |
$ 931 |
$ -512 |
2,800 |
| Syneos Health Inc |
$ 4,464 |
$ 5,419 |
$ 71 |
25,000 |
| Guardant Health Inc |
$ 2,841 |
$ 510 |
$ -508 |
1,100 |
| Fortrea Holdings Inc |
$ 2,526 |
- |
$ 0 |
- |
| Radnet Inc |
$ 1,720 |
$ 1,528 |
$ 12 |
8,700 |
| Veracyte Inc |
$ 1,629 |
$ 329 |
$ -29 |
677 |
| National Research Corporation |
$ 1,135 |
$ 148 |
$ 29 |
- |
| Fulgent Genetics Inc |
$ 824 |
$ 307 |
$ -50 |
284 |
| Viridian Therapeutics Inc |
$ 668 |
$ 1 |
$ -198 |
- |
| Lightwave Logic Inc |
$ 562 |
- |
$ -21 |
10 |
| Omniab Inc |
$ 495 |
- |
$ -37 |
- |
| Somalogic Inc |
$ 437 |
$ 101 |
$ -141 |
- |
| Castle Biosciences Inc |
$ 431 |
$ 110 |
$ 19 |
200 |
| Mdxhealth Sa |
$ 429 |
$ 37 |
$ -44 |
- |
| Caredx Inc |
$ 411 |
$ 309 |
$ -84 |
446 |
| Nano x Imaging Ltd |
$ 330 |
$ 9 |
$ -113 |
- |
| Nuoncology Labs Inc |
$ 322 |
- |
$ 0 |
- |
| Maxcyte inc |
$ 317 |
$ 41 |
$ -33 |
- |
| Zymergen Inc. |
$ 251 |
$ 15 |
$ -365 |
- |
| Butterfly Network Inc |
$ 232 |
$ 69 |
$ -107 |
- |
| Celcuity Inc |
$ 210 |
- |
$ -49 |
- |
| Luna Innovations Inc |
$ 200 |
$ 109 |
$ -5 |
236 |
| Fresh2 Group Ltd |
$ 167 |
$ 2 |
$ -15 |
- |
| Bionexus Gene Lab Corp |
$ 157 |
$ 10 |
$ -1 |
- |
| Invitae Corporation |
$ 151 |
$ 481 |
$ -451 |
1,500 |
| Absci Corp |
$ 124 |
$ 9 |
$ -112 |
- |
| Biodesix Inc |
$ 112 |
$ 42 |
$ -66 |
- |
| Kushco Holdings Inc |
$ 104 |
$ 114 |
$ -25 |
29 |
| Inotiv Inc |
$ 82 |
$ 582 |
$ -338 |
- |
| Enzo Biochem Inc |
$ 68 |
$ 71 |
$ -46 |
412 |
| Personalis Inc |
$ 58 |
$ 67 |
$ -110 |
- |
| Sera Prognostics Inc |
$ 55 |
$ 0 |
$ -42 |
- |
| Dermtech Inc |
$ 52 |
$ 13 |
$ -120 |
- |
| Science 37 Holdings Inc |
$ 46 |
- |
$ 77 |
- |
| Exagen Inc |
$ 40 |
$ 53 |
$ 13 |
- |
| Centogene N v |
$ 28 |
$ 53 |
$ -36 |
500 |
| Check cap Ltd |
$ 25 |
- |
$ 17 |
- |
| Medtech Acquisition Corporation |
$ 24 |
- |
$ -1 |
- |
| Psychemedics Corp |
$ 21 |
$ 23 |
$ -2 |
- |
| American Shared Hospital Services |
$ 15 |
$ 20 |
$ 1 |
- |
| Malachite Innovations Inc |
$ 14 |
$ 11 |
$ 0 |
- |
| Akumin Inc |
$ 12 |
$ 751 |
$ -154 |
- |
| Bioaffinity Technologies Inc |
$ 8 |
$ 0 |
$ -11 |
- |
| Ispecimen inc |
$ 6 |
$ 10 |
$ -11 |
- |
| Halberd Corporation |
$ 5 |
- |
$ 0 |
- |
| Evolutionary Genomics Inc |
$ 5 |
$ 0 |
$ -4 |
- |
| Vyant Bio Inc |
$ 5 |
$ 1 |
$ -23 |
- |
| Biocept Inc |
$ 2 |
- |
$ -39 |
135 |
| Grapefruit Usa Inc |
$ 1 |
$ 0 |
$ -4 |
- |
| Opgen inc |
$ 1 |
$ 3 |
$ -36 |
- |
| Advanced Container Technologies Inc |
$ 1 |
$ 5 |
$ -1 |
22 |
| U s Stem Cell Inc |
$ 0 |
$ 0 |
$ -3 |
- |
| Hh and l Acquisition Co |
- |
- |
$ 9 |
- |
| Burning Rock Biotech Limited |
- |
$ 82 |
$ -141 |
- |
| Genetron Holdings Ltd |
- |
$ 94 |
$ -118 |
862 |
| Laboratory Corporation Of America Holdings |
- |
$ 14,877 |
$ 1,281 |
75,500 |
| Delwinds Insurance Acquisition Corp |
- |
- |
$ 0 |
- |
| Renalytix Plc |
- |
$ 1 |
$ -34 |
- |
| Aclarion Inc |
- |
$ 0 |
$ -5 |
- |
| Data Knights Acquisition Corp |
- |
- |
$ -3 |
- |
| Medical Laboratories Industry |
$ 236,486 |
$ 98,246 |
$ 516 |
417,662 |
Recent News from Medical Laboratories Industry |
|
Aclarion Inc
In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.
|
|
|
Delwinds Insurance Acquisition Corp
Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.
|
|
|
Invitae Corporation
Introduction
Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.
|
|
|
Bionexus Gene Lab Corp
Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.
|
|
|
Biocept Inc
Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.
|
|
|
Opgen Inc
OPGEN INC: A STRUGGLING PLAYER IN THE MEDICAL LABORATORIES INDUSTRY
Opgen Inc, a leading player in the Medical Laboratories industry, has recently reported weak business performance for the quarter ending June 30, 2023. The company's losses have improved, but it still faces significant challenges that have led to a decline in revenue and an increase in the shortfall per share.
During the second quarter of 2023, Opgen Inc experienced a drop in revenue by -23.89%, with only $0.74 million generated compared to $0.97 million in the same period last year. This decline is concerning, especially considering that the overall industry witnessed a revenue gain during this time. The company's inability to capitalize on this industry growth raises questions about its competitive position and business strategy.
|
|
|
Psychemedics Corp
Weak orders and declining revenue have led to increased losses for Psychemedics Corp in the second quarter of 2023. The company reported a net loss per share of $-0.13, up from $-0.06 in the previous year, while revenue decreased by -22.325% to $5.06 million. This represents a significant setback for the company, especially when compared to the rest of the Medical Laboratories sector, which experienced a revenue gain of 3.90% during the same period.
The decline in revenue is a concerning trend for Psychemedics Corp, as it indicates a decrease in demand for its products and services. This is further supported by the reduction in accounts receivable, which now stands at $4.0 million. Analysts believe that this decline is directly linked to the slowing demand and weak orders the company is facing.
|
|
|
Hh And L Acquisition Co
As a shareholder of Hh And L Acquisition Co, the recent financial results for the April to June 2023 reporting cycle have left me both surprised and concerned. Having high expectations for the company's progress, it is disheartening to witness a significant operating deficit during this period.
The Medical Laboratories company's operating deficit of $-0.495455 million portrays a troubling picture. It signals a moderation in business growth, contrary to what shareholders had anticipated. However, when we examine the same period a year prior, we find a glimmer of hope. The company's operating deficit was even higher at $-0.779122 million. Thus, it can be inferred that Hh And L Acquisition Co has managed to compete more economically over time.
|
|
|
Data Knights Acquisition Corp
The Medical Laboratories sector plays a crucial role in providing essential diagnostic services to both individuals and healthcare institutions. As the reporting cycle for April to June 2023 progresses, several companies within this sector have reported their financial results. One such company is DKDCU, which recently announced an operating shortfall of $-0.285454 million for the mentioned period. This article aims to provide an explanation of DKDCU's performance, comparing it to the previous financial interval and highlighting the significance of the recent numbers.
Improvement in Economic Efficiency:
DKDCU, an evolving entity in the Medical Laboratories sector, has showcased improved economic efficiency in the April to June 2023 interval as compared to the previous year. The company reported an operating shortfall of $-0.794495 million for the corresponding period in 2022, while the current shortfall indicates a significant reduction. This improvement indicates that DKDCU has conducted its business more economically, resulting in a decrease in operating losses.
|
|
|
American Shared Hospital Services
In the midst of a challenging economic climate, Medical Laboratories company has managed to showcase impressive revenue growth, outperforming its industry contemporaries. While there were signs of progress, the company fell short of breaking even in the April to June 2023 timeframe. Despite this setback, Medical Laboratories company has displayed promising potential and continues to attract attention from investors.
Strong Revenue Growth:
Medical Laboratories company reported a significant year-on-year revenue growth of 9.615%, amounting to $5.52 million in the April to June 2023 period. This growth is notably higher than the industry average, as the rest of the Medical Laboratories sector registered a 3.90% increase in revenue during the same timeframe. Such exceptional growth indicates the company's ability to capture market share and enhance its position within the industry.
|
|
|
|
|
|
